시장보고서

상품코드

1781969

구속성 펩티드 의약품 시장 : 펩티드 유형별, 치료 영역별, 합성 방법별, 투여 경로별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모 및 점유율, 예측(2025-2032년)

Constrained Peptide Drugs Market, By Peptide Type, By Therapeutic Area, By Synthesis Method, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 06월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 316 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

구속성 펩티드 의약품 시장 규모는 2024년에 15억 6,032만 달러에 달하며, 2025-2032년에 16.20%의 CAGR로 확대

구속성 펩티드 의약품 시장 역학

만성질환 유병률 증가로 시장 수요 증가 촉진

만성질환의 유병률 증가는 세계 구속성 펩티드 의약품 시장의 성장을 가속하고 있습니다. CDC에 따르면 미국 성인 10명 중 6명이 만성질환을 앓고 있으며, 이는 구속성 펩티드 의약품과 같은 표적치료제에 대한 수요를 촉진하고 있습니다. 또한 펩티드 안정화의 발전도 시장 성장을 가속하는 요인 중 하나로 예측됩니다. 그러나 높은 제조 비용과 규제 문제가 향후 수년간 시장 성장에 걸림돌이 될 것으로 예측됩니다. 반대로, 종양학 분야에서의 용도 확대와 개별화 투자 증가는 개별 환자 프로파일에 맞게 설계된 펩티드 의약품에 대한 기회를 제공합니다.

구속성 펩티드 의약품 시장 : 주요 고려사항

제약이 많은 펩티드 의약품 시장 - 주요 인사이트

당사의 리서치 애널리스트들이 공유한 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 동안 매년 약 16.20%의 연평균 복합 성장률(CAGR)을 보일 것으로 추정됩니다.

펩티드 유형별로는 환형 펩티드가 2024년 가장 높은 시장 점유율을 보였습니다.

치료 영역별로는 2024년에는 종양 영역이 주요 치료 영역이 될 것입니다.

합성 방법별로는 고체상 펩티드 합성이 2024년 주요 합성 방법이었습니다.

투여 경로별로는 2024년 피하투여가 가장 높은 비중을 차지할 것으로 예측됩니다.

최종사용자별로 보면 병원이 2024년 최고

지역별로는 북미가 2024년 매출 1위를 기록했습니다.

구속성 펩티드 의약품 시장 : 세분화 분석

구속성 펩티드 의약품 세계 시장은 펩티드 유형, 치료 영역, 합성 방법, 투여 경로, 최종사용자, 지역에 따라 세분화됩니다.

시장은 펩티드 유형에 따라 고리형 펩티드, 대환형 펩티드, D-펩티드, 스테이플드 펩티드의 네 가지 범주로 나뉩니다. 순환 펩티드 부문은 다른 펩티드 유형에 비해 안정성이 높고, 생체 이용률이 개선되고, 치료 분야에 널리 적용되어 예측 기간 중 주요 시장 점유율을 차지할 것으로 예측됩니다.

시장은 치료 영역별로 감염성 질환, 심혈관 질환, 중추신경계 질환, 종양, 대사성 질환으로 크게 두 가지로 분류됩니다. 종양 분야는 암 발병률 증가와 암 표적 치료에서 펩티드 의약품의 효과로 인해 전 세계 구속성 펩티드 의약품 시장에서 주요 시장 점유율을 차지할 것으로 예측됩니다.

구속성 펩티드 의약품 시장 : 지역별 분석

북미는 첨단 의료 인프라, R&D 투자 증가, 혁신적인 치료법의 높은 채택률에 힘입어 예측 기간 중 구속성 펩티드 의약품 시장의 주요 점유율을 차지할 것으로 예측됩니다. 한편, 아시아태평양은 의료에 대한 인식 증가, 환자 수 증가, 신흥 국가의 생명공학 및 제약 분야 투자 증가로 인해 가장 빠른 속도로 성장할 것으로 예측됩니다.

구속성 펩티드 의약품 시장 : 경쟁 구도

표적화되고 안정적인 치료제에 대한 수요가 증가하면서 구속성 펩티드 의약품의 기술 혁신이 가속화되고 있습니다. 각 업체들은 펩티드 안정화 기술의 발전과 전달 방법의 개선에 집중하여 유효성과 환자 순응도를 향상시키고 있습니다. 연구기관과의 전략적 제휴 및 공동연구를 통해 의약품 개발을 가속화하고 제품 파이프라인을 확장할 수 있습니다. 또한 제조 능력 확대와 신흥 시장 진출에 대한 투자는 증가하는 의료 수요에 대응하는 데 도움이 될 것입니다. 맞춤형 의료와 신규 펩티드 제제 개발에 중점을 두면서 진화하는 상황에서 경쟁 구도는 더욱 강화될 것입니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석 : 구속성 펩티드 의약품 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- Amgen Inc.
- Pfizer Inc.
- Novartis AG
- Merck &Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Sanofi SA
- Bicycle Therapeutics PLC
- Bristol-Myers Squibb Company
- Aileron Therapeutics, Inc.
- Eli Lilly and Company
- Aileron Therapeutics Inc.
- Spexis AG
- Santhera Pharmaceuticals
- Protagonist Therapeutics Inc.
- Union Chimique Belge SA(UCB)
- Biosynth(Pepscan)
- Creative Peptides
- Pepticom Ltd.
- Bio-Synthesis Inc.
- PeptiDream Inc.
- CPC Scientific Inc.
- Chugai Pharmaceutical Co. Ltd.
- Circle Pharma
- Others

제14장 AnalystView의 전방위적 분석

KSA 25.08.08

REPORT HIGHLIGHT

Constrained peptide drugs market size was valued at US$ 1,560.32 Million in 2024, expanding at a CAGR of 16.20% from 2025 to 2032.

Constrained peptide drugs are specially designed molecules where the peptide's structure is chemically "locked" into a stable shape. This constraint improves their stability, enhances binding to specific targets, and increases resistance to degradation by enzymes in the body. These features make them highly effective in treating diseases by precisely interacting with biological molecules, offering advantages over traditional peptides such as improved potency, selectivity, and longer-lasting therapeutic effects.

Constrained Peptide Drugs Market- Market Dynamics

Increasing prevalence of chronic diseases to propel market demand

The rising prevalence of chronic diseases is driving the growth of the global constrained peptide drugs market. According to the CDC, approximately 6 in 10 adults in the U.S. have a chronic disease, driving demand for targeted therapies like constrained peptide drugs. Besides, advancements in peptide stabilization is another factor projected to boost the market growth. However, high production costs and regulatory challenges is expected to hamper the market growth in the coming years. On the contrary, expanding applications in oncology and increasing investment in personalized, providing opportunities for peptide drugs designed for individual patient profiles.

Constrained Peptide Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.20% over the forecast period (2025-2032)

Based on Peptide Type segmentation, cyclized peptides was predicted to show maximum market share in the year 2024

Based on Therapeutic Area segmentation, oncology was the leading Therapeutic Area in 2024

Based on Synthesis Method segmentation, solid phase peptide synthesis was the leading Synthesis Method in 2024

Based on Route of Administration segmentation, subcutaneous was the leading Route of Administration in 2024

Based on end user segmentation, Hospital was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Constrained Peptide Drugs Market- Segmentation Analysis:

The Global Constrained Peptide Drugs Market is segmented on the basis of Peptide Type, Therapeutic Area, Synthesis Method, Route of Administration, End User, and Region.

The market is divided into four categories based on Peptide Type: cyclized peptides, macrocyclic peptides, D-peptides, and stapled peptides. The cyclized peptides segment is expected to hold the major market share during the forecast period, driven by their enhanced stability, improved bioavailability, and widespread applications in therapeutic areas compared to other peptide types.

The market is divided into two categories based on Therapeutic Area: infectious diseases, cardiovascular diseases, Cns Disorders, oncology, and metabollic disorders. The oncology segment is expected to hold the major market share in the global constrained peptide drugs market, due to increasing cancer prevalence and the effectiveness of peptide drugs in targeted cancer therapies.

Constrained Peptide Drugs Market- Geographical Insights

The North America region is expected to hold the major constrained peptide drugs market share during the forecast period, driven by advanced healthcare infrastructure, increased R&D investments, and high adoption of innovative therapies. Meanwhile, the Asia-Pacific region is projected to grow at the fastest rate due to rising healthcare awareness, expanding patient populations, and growing investments in biotechnology and pharmaceutical sectors across emerging economies.

Constrained Peptide Drugs Market- Competitive Landscape:

Rising demand for targeted and stable therapeutics drives innovation in constrained peptide drugs. Companies focus on advancing peptide stabilization technologies and enhancing delivery methods to improve efficacy and patient compliance. Strategic partnerships and collaborations with research institutes accelerate drug development and expand product pipelines. Additionally, investments in expanding manufacturing capabilities and penetrating emerging markets help capitalize on growing healthcare needs. Emphasis on personalized medicine and novel peptide formats further strengthens competitive positioning in this evolving landscape.

Recent Developments:

In January 2025, Bicycle Therapeutics plc shared updated Phase 1 combination results for zelenectide pevedotin with pembrolizumab in cisplatin-ineligible metastatic urothelial cancer patients, along with key accomplishments and strategic plans for 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen Inc.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Sanofi S.A.
Bicycle Therapeutics PLC
Bristol-Myers Squibb Company
Aileron Therapeutics, Inc.
Eli Lilly and Company
Aileron Therapeutics Inc.
Spexis AG
Santhera Pharmaceuticals
Protagonist Therapeutics Inc.
Union Chimique Belge S.A. (UCB)
Biosynth (Pepscan)
Creative Peptides
Pepticom Ltd.
Bio-Synthesis Inc.
PeptiDream Inc.
CPC Scientific Inc.
Chugai Pharmaceutical Co. Ltd.
Circle Pharma
Others

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY PEPTIDE TYPE- MARKET ANALYSIS, 2019 - 2032

Cyclized Peptides
Macrocyclic Peptides
D-Peptides
Stapled Peptides

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Infectious Diseases
Cardiovascular Diseases
Cns Disorders
Oncology
Metabollic Disorders

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY SYNTHESIS METHOD- MARKET ANALYSIS, 2019 - 2032

Solid Phase Peptide Synthesis
Recombinant Technology

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous
Transdermal
Subcutaneous

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Research Institutes
Pharmaceutical Companies

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Constrained Peptide Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Constrained Peptide Drugs Market Snippet by Peptide Type
- 2.1.2. Constrained Peptide Drugs Market Snippet by Therapeutic Area
- 2.1.3. Constrained Peptide Drugs Market Snippet by Synthesis Method
- 2.1.4. Constrained Peptide Drugs Market Snippet by Route of Administration
- 2.1.5. Constrained Peptide Drugs Market Snippet by End User
- 2.1.6. Constrained Peptide Drugs Market Snippet by Country
- 2.1.7. Constrained Peptide Drugs Market Snippet by Region
2.2. Competitive Insights

3. Constrained Peptide Drugs Key Market Trends

3.1. Constrained Peptide Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Constrained Peptide Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Constrained Peptide Drugs Market Opportunities
3.4. Constrained Peptide Drugs Market Future Trends

4. Constrained Peptide Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Constrained Peptide Drugs Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Constrained Peptide Drugs Market Landscape

6.1. Constrained Peptide Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Constrained Peptide Drugs Market - By Peptide Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Peptide Type, 2024 & 2032 (%)
- 7.1.2. Cyclized Peptides
- 7.1.3. Macrocyclic Peptides
- 7.1.4. D-Peptides
- 7.1.5. Stapled Peptides

8. Constrained Peptide Drugs Market - By Therapeutic Area

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
- 8.1.2. Infectious Diseases
- 8.1.3. Cardiovascular Diseases
- 8.1.4. Cns Disorders
- 8.1.5. Oncology
- 8.1.6. Metabollic Disorders

9. Constrained Peptide Drugs Market - By Synthesis Method

9.1. Overview
- 9.1.1. Segment Share Analysis, By Synthesis Method, 2024 & 2032 (%)
- 9.1.2. Solid Phase Peptide Synthesis
- 9.1.3. Recombinant Technology

10. Constrained Peptide Drugs Market - By Route of Administration

10.1. Overview
- 10.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
- 10.1.2. Oral
- 10.1.3. Intravenous
- 10.1.4. Transdermal
- 10.1.5. Subcutaneous

11. Constrained Peptide Drugs Market - By End User

11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Research Institutes
- 11.1.4. Pharmaceutical Companies

12. Constrained Peptide Drugs Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Constrained Peptide Drugs Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Constrained Peptide Drugs Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Constrained Peptide Drugs Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Constrained Peptide Drugs Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Constrained Peptide Drugs Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Constrained Peptide Drugs Industry

13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. Amgen Inc.
- 13.2.2. Pfizer Inc.
- 13.2.3. Novartis AG
- 13.2.4. Merck & Co., Inc.
- 13.2.5. F. Hoffmann-La Roche Ltd.
- 13.2.6. Sanofi S.A.
- 13.2.7. Bicycle Therapeutics PLC
- 13.2.8. Bristol-Myers Squibb Company
- 13.2.9. Aileron Therapeutics, Inc.
- 13.2.10. Eli Lilly and Company
- 13.2.11. Aileron Therapeutics Inc.
- 13.2.12. Spexis AG
- 13.2.13. Santhera Pharmaceuticals
- 13.2.14. Protagonist Therapeutics Inc.
- 13.2.15. Union Chimique Belge S.A. (UCB)
- 13.2.16. Biosynth (Pepscan)
- 13.2.17. Creative Peptides
- 13.2.18. Pepticom Ltd.
- 13.2.19. Bio-Synthesis Inc.
- 13.2.20. PeptiDream Inc.
- 13.2.21. CPC Scientific Inc.
- 13.2.22. Chugai Pharmaceutical Co. Ltd.
- 13.2.23. Circle Pharma
- 13.2.24. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us